# Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Source: https://onco.cc/trials/nct04793958/  
OnCo record `nct04793958` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cetuximab in colorectal cancer, run by Mirati Therapeutics Inc., active and no longer recruiting.

## Summary

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) is a phase 3 interventional study registered as NCT04793958 by Mirati Therapeutics Inc., with 461 participants enrolled, started 2021-06-24 and due to reach its primary completion in 2026-01-16. Interventions recorded: MRTX849, Cetuximab, mFOLFOX6 Regimen, FOLFIRI Regimen. Conditions listed: Advanced Colorectal Cancer, Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04793958
- Phase: 3
- Setting: A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy
- Sponsor: Mirati Therapeutics Inc.
- Enrolled: 461

## Sources

- ClinicalTrials.gov NCT04793958: https://clinicaltrials.gov/study/NCT04793958

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct04793958.json